Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

Graft-Versus-Host disease market Insights. DelveInsight's Graft-Versus-Host Disease Market report offers an in-depth understanding of the epidemiology and ...

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

Spanish firm Grifols has submitted a Biologics License Application (BLA) for its new potential fibrinogen treatment to the US ...

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets ...

HOUSTON, TEXAS / ACCESSWIRE / January 9, 2025 / The Golden Gift announced today that affordable plasma interventions can have significant health and economic benefits to prevent or manage age-related ...

NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

UCB, a global biopharmaceutical company, and XtalPi, a global leader in AI drug discovery, today announced a license agreement ...

Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...